Prima Biomed Limited
(ASX:PRR) has unveiled a new clinical trial of IMP 321, a drug used to inhibit metastic melanoma.
The Human Research Ethics Committee at the Greenslopes Private Hospital in Queensland has cleared the study protocol.
The company is currently striving to become a leader in the development of immunotherapeutic products for the treatment of cancer.
The first patient is expected to enter the study in 2016.
Prima Biomed reported a net loss of $32.15 million at 30 June 2015.
